About us

Energenesis Biomedical Co., Ltd. Obtains Patent Grant in Canada for 'METHODS FOR TREATING DIABETIC ULCER' Following PCT National Phase Entry

EB Receives a letter from the Ministry of Health and Welfare in which the Ministry has given its approval to conduct a Phase II IND clinical trial of F703EB

Energenesis Biomedical Wins the 22nd Taiwan National Innovation Award

Energenesis Biomedical Receives FDA Clearance for Phase II Trial of ENERGI-F703EB

Energenesis Biomedical Announces IND Submission to the U.S. FDA for Phase II Clinical Trial of ENERGI-F703EB Cream

Energenesis Biomedical is invited to attend Taishin’s “2025 Investor Conference"

Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease

Energenesis Biomedical and Medvisis Switzerland AG Sign MOU for F703DFU Commercialization in Switzerland

Energenesis Biomedical and Phison Sign MOU to Advance AI-Driven Drug Development

Energenesis Biomedical Co., Ltd. has signed a Memorandum of Understanding (MOU) with DEBRA Research gGmbH to collaborate on the development of F703EB.